"MATH+" Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion detailing mechanistic rationale without new human trial data
PubMed 35317360 · doi:10.14740/jocmr4658
What was done
The authors, representing the Front-Line COVID-19 Critical Care Alliance (FLCCC), compiled a narrative review describing the clinical and mechanistic rationale for the "MATH+" treatment protocol—consisting of methylprednisolone, ascorbic acid, thiamine, heparin, and supportive co-interventions—for hospitalized COVID-19 patients with acute respiratory failure.
What was found
The abstract outlines the development of the protocol based on frontline clinician discussions, early observational impressions, and published in-vitro, preclinical, and clinical literature. No quantitative clinical trial data, sample sizes, or numerical outcome measures are reported in the abstract.
Why it matters
It articulates the clinical reasoning and mechanistic hypotheses behind a widely discussed multi-modal treatment regimen proposed during the COVID-19 pandemic.
Limits
This is a narrative framework and expert opinion review rather than an empirical trial or systematic review. The abstract reports no primary human outcome data, control comparators, or statistical evaluations to assess efficacy or safety.
Cited by
- supports Dr. Pierre Kory published papers on using intravenous thiamine along with corticosteroids in ICU patients for COVID-19.